Navigation Links
Unilife Corporation Announces Completion of Offering of 8,250,000 Shares of Common Stock
Date:11/21/2011

YORK, Pa., Nov. 21, 2011 /PRNewswire/ -- Unilife Corporation (NASDAQ: UNIS / ASX: UNS) ("Unilife" or the "Company") today announced the successful closing of an underwritten registered public offering to U.S. institutions.

Unilife has issued 8,250,000 shares of common stock at the offering price of $4.35 per share.  In connection with the offering, the Company also granted the underwriters a 30-day option to purchase up to an additional 1,237,500 shares of common stock to cover over-allotments, if any.  The net proceeds to Unilife from the offering are $33.8 million, exclusive of any proceeds attributable to the underwriters' possible exercise of their over-allotment option.

Unilife expects to use the net proceeds from this offering to fund the continued development and commercial supply of its diversified portfolio of advanced drug delivery systems, and to drive the expansion of its workforce to support anticipated customer demands.

Jefferies & Company, Inc. acted as sole book-running manager for the offering.  Leerink Swann LLC acted as co-lead manager for the offering, and Griffin Securities, Inc. acted as co-manager for the offering.

This announcement shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Unilife, nor shall there be any sale of securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.  This press release is being issued pursuant to and in accordance with Rule 134 of the Securities Act of 1933, as amended.

About Unilife Corporation Unilife Corporation (NASDAQ: UNIS / ASX: UNS) is a U.S. based developer and commercial supplier of a diversified portfolio of advanced drug delivery systems.  Unilife collaborates with pharmaceutical and biotechnology companies seeking to optimize drug lifecycles and generate differentiation for their brand in competitive therapeutic markets through the use of innovative devices that can improve patient care, protect healthcare workers and prevent disease. Unilife has developed a broad portfolio of drug delivery systems in direct response to unmet market needs for macromolecule injectable drugs including biologics. 

Safe Harbor Statement This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our Annual Report on Form 10-K, in the final prospectus supplement and related prospectus relating to the offering and those described from time to time in other reports which we file with the Securities and Exchange Commission. 

General: UNIS-G Investor Contacts (US):  Investor Contacts (Australia)Todd Fromer / Garth RussellStuart FineJeff CarterKCSA Strategic CommunicationsCarpe DM IncUnilife CorporationP: + 1 212-682-63P: + 1 908 469 1788P: + 61 2 8346 6500


'/>"/>

SOURCE Unilife Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Unilife Corporation Announces Pricing of Offering of 8,250,000 Shares of Common Stock
2. Unilife Corporation Announces Proposed Public Offering of Common Stock
3. Unilife Corporation Announces Financial Results for Fiscal Year 2012 First Quarter
4. Unilife Corporation to Announce Financial Results For Fiscal 2012 First Quarter on Wednesday, November 9, 2011
5. Unilife Announces Internet Availability of Proxy Materials for its 2011 Annual Meeting of Stockholders
6. Unilife Wins Supply Contract with Nations Largest Healthcare Alliance
7. Unilife CEO to Purchase an Additional U.S. $500,000 in Company Shares by September 30, 2011
8. Unilife to Present at the Jefferies 2011 Global Healthcare Conference in London
9. Unilife to Present at the 2011 UBS Global Life Sciences Conference in New York City
10. Unilife Develops Proprietary Portfolio of Wearable Subcutaneous Infusion Devices for the Self-Administration of Large Volume Drugs by Patients
11. Unilife to Participate in Two Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2017)... 29, 2017  Cellect Biotechnology Ltd. (NASDAQ: ... enables the functional selection of stem cells, today provided ... first quarter ended March 31 st , 2017. ... in the first quarter of 2017," said Dr. Shai ... announced the treatment of the first blood cancer patient ...
(Date:5/23/2017)... 23, 2017  Leaf Healthcare, recognized for developing ... for pressure ulcer prevention, will unveil its comprehensive ... Critical Care Nurses, National Teaching Institute and Critical ... The Leaf Patient Monitoring System is the first ... environment.  The system seamlessly tracks patient movement throughout ...
(Date:5/18/2017)... , May 17, 2017  Bayer announced today that ... will be presented at the 53 rd Annual ... taking place June 2-6 in Chicago ... ASCO span prostate, colorectal, liver and thyroid cancers, as ... the Phase II CHRONOS-1 trial of copanlisib in patients ...
Breaking Medicine Technology:
(Date:6/20/2017)... ... ... With certifications and experience that puts them at the top of the field ... currently accepting new patients at their practice for these custom clear aligners. These qualified ... why they offer the latest in modern dental techniques to ensure that all their ...
(Date:6/20/2017)... ... June 20, 2017 , ... Many ... their regulatory principles, the research team developed expressRNA, a web platform encompassing computational ... This reveals at nucleotide resolution the ‘RNA maps’, which demonstrate that RBPs bind ...
(Date:6/20/2017)... ... June 20, 2017 , ... Total Security Integrated Systems, one ... the partner of choice by Amtrak to fulfill several projects in various Northeast ... long-distance intercity service in the contiguous United States. Security Executives at the company ...
(Date:6/20/2017)... ... June 20, 2017 , ... Uniworld Boutique River Cruise Collection ... latest all-inclusive boutique ship, S.S. Joie de Vivre . What really sets this ... France’s Seine River and designed small enough to dock directly in Paris. With The ...
(Date:6/20/2017)... ... June 20, 2017 , ... The law firm of Momkus McCluskey Roberts ... president of the DuPage County Bar Association’s Board of Directors. Cassioppi officially took on ... the Drake in Oak Brook. Momkus McCluskey Roberts LLC attorney Stacey A. McCullough was ...
Breaking Medicine News(10 mins):